AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

Wet lab experiments are slow and expensive, forcing scientists to pursue safer, incremental hypotheses. AI models can computationally test riskier, 'home run' ideas before committing lab resources. This de-risking makes scientists less hesitant to explore breakthrough concepts that could accelerate the field.

A classical, bottom-up simulation of a cell is infeasible, according to John Jumper. He sees the more practical path forward as fusing specialized models like AlphaFold with the broad reasoning of LLMs to create hybrid systems that understand biology.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

In high-stakes fields like pharma, AI's ability to generate more ideas (e.g., drug targets) is less valuable than its ability to aid in decision-making. Physical constraints on experimentation mean you can't test everything. The real need is for tools that help humans evaluate, prioritize, and gain conviction on a few key bets.

Counterintuitively, Nobel laureate John Jumper's path to AI began not with abundant resources, but as a way to use sophisticated algorithms to compensate for a lack of computational power for protein simulations during his PhD.

Following the success of AlphaFold in predicting protein structures, Demis Hassabis says DeepMind's next grand challenge is creating a full AI simulation of a working cell. This 'virtual cell' would allow researchers to test hypotheses about drugs and diseases millions of times faster than in a physical lab.

Current LLMs fail at science because they lack the ability to iterate. True scientific inquiry is a loop: form a hypothesis, conduct an experiment, analyze the result (even if incorrect), and refine. AI needs this same iterative capability with the real world to make genuine discoveries.

The founder of AI and robotics firm Medra argues that scientific progress is not limited by a lack of ideas or AI-generated hypotheses. Instead, the critical constraint is the physical capacity to test these ideas and generate high-quality data to train better AI models.